The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury

International Journal of Impotence Research

Volumn 22, Issue 5, 2010, Pages 291-297

  Kim, H ^a   Sohn, D W ^a   Kim, S D ^b   Hong, S H ^a   Suh, H J ^a   Lee, C B ^a   Kim, S W ^a  

^a The Catholic University of Korea   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

Author keywords

corpus cavernosum; erectile dysfunction; mirodenafil

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MIRODENAFIL; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NERVE INJURY; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; CYCLIC GMP; DISEASE MODELS, ANIMAL; ERECTILE DYSFUNCTION; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PENILE ERECTION; PERIPHERAL NERVES; PHOSPHODIESTERASE 5 INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 77958172469     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2010.19     Document Type: Article

References (22)

1. Yee DS, Ahlering TE. Radical prostatectomy: a current perspective. J Urol 2007;178:376-377.
2. Benoit RM, Naslund MJ, Cohen JK. Complications after radical retropubic prostatectomy in the medicare population. Urology 2000;56:116-120.
3. Marien TP, Lepor H. Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?. BJU Int 2008;102:1581-1584.
4. Ahlering TE, Roddriquez E, Sharecky DW. Overcoming obstacles: nerve-sparing issues in radical prostatectomy. J Endourol 2008;22:745-750.
5. Dubbleman YD, Wildhagen MF, Dohle GR. Penile vascular evaluation and sexual function before and after radical retropubic prostatectomy: 5-year follow up. Int J Androl 2008;31:483-489.
6. Ohebshalom M, Parker M, Waters B, Flanagan R, Mulhall JP. Erectile haemodynamic status after radical prostatectomy correlates with erectile functional outcome. BJU Int 2008;102:592-596.
7. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96:257-280.
8. Namiki S, Kwan L, Kagawa-singer M, Arai Y, Litwin MS. The effect of erectile function on the use of phosphodiesterase-5 inhibitor after radical prostatectomy in Japanese and U. S. men. Urology 2008;71:901-905.
9. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006;68:429-435.
10. Lee SK, Kim Lee SK, Kim Y, Kim TK, Im GJ, Lee BY et al. Determination of Mirodenafil and sildenafil in the plasma and corpus of SD male rats. J Pharm Biomed Anal 2009;49:513-518.
11. Choi YH, Lee YS, Bae SH, Kim TK, Lee BY, Lee MG. Dosedependent pharmacokinetics and first-pass effects of Mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 2009;30:305-317.
12. Jung JY, Kim SK, Kim BS, Lee SH, Park YS, Kim SJ et al. The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, Mirodenafil (SK3530), in rabbits with acute spinal cord injury. J Vet Med Sci 2008;70:1199-1204.
13. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC et al. Efficacy and safety of Mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:2672-2680.
14. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res 2001;13] (Suppl 3): S8-S17.
15. Heaton JP. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev 2000;24:561-569.
16. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Machtens SA et al. Systemic and cavernous plasma levels of vasoactive intestinal polypeptide during sexual arousal in healthy males. World J Urol 2002;20:59-63.
17. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526. (Pubitemid 17085822)
18. Dusting GJ. Nitric oxide in cardiovascular disorders. J Vasc Res 1995;32:143-161.
19. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term treatment with vardenafil on the development of the fibrotic plaque in a rat model of Peyronie's disease. BJU Int 2006;97:625-633.
20. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase on the physiology and pathology of penile erection. Curr Pharm Des 2005;11:4041-4046.
21. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Import Res 1998;10:113-120.
22. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of Alprostadil: results of a prospective randomized trial. J Urol 1997;158:1408-1410.